Leerink Partners Downgrades Humana to Market Perform, Lowers Price Target to $250
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has downgraded Humana from Outperform to Market Perform and reduced its price target from $400 to $250.
October 02, 2024 | 4:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Leerink Partners downgraded Humana from Outperform to Market Perform and lowered the price target from $400 to $250, indicating a less optimistic outlook.
The downgrade from Outperform to Market Perform suggests that the analyst sees less potential for Humana's stock to outperform the market. The significant reduction in the price target from $400 to $250 indicates a bearish outlook, likely leading to a negative short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100